Angelini Pharma Company

Media

Angelini Pharma Company
  • Home
  • About Us
  • About Epilepsy
  • Media
    • Press Release
  • Contact
  • News + Press Releases
  • 2021
  • 2020
  • 2019

Arvelle Announces European Medicines Agency Acceptance of the Marketing Authorization Application (MAA) for Cenobamate

The MAA seeks authorisation for the adjunctive treatment of focal-onset seizures in adult patients with epilepsy Zug, Switzerland, 26 March 2020…

Press Release March 26, 2020

Appointment of Dr Otto Schwarz as Independent Director and Chairman of the Board

Zug, Switzerland, December 4, 2019 – Arvelle Therapeutics GmbH (“Arvelle”), an emerging biopharmaceutical company focused on bringing…

Press Release December 4, 2019

SK Life Science, Inc. Receives US FDA Approval for cenobamate tablets for the Treatment of Partial-Onset Seizures in Adults with Epilepsy

Approval based on pivotal trials that assessed the efficacy and safety of cenobamate Arvelle Therapeutics has exclusive rights to develop and…

Press Release November 25, 2019

Arvelle Therapeutics wins Series A Finance Raise of the Year Award

Zug, Switzerland, November 20, 2019 – Arvelle Therapeutics GmbH, an emerging biopharmaceutical company focused on bringing innovative treatments to…

Press Release November 20, 2019

Results of Randomized Study Evaluating the Safety and Efficacy of Cenobamate in Patients with Uncontrolled Focal-Onset Epilepsy Published in The Lancet Neurology

Cenobamate significantly reduced focal seizure frequency, with as many as 20% of patients reaching zero seizures during the study’s maintenance…

Press Release November 14, 2019

Arvelle Therapeutics Strengthens Management Team with Key New Hires

Appoints Petra Molan as Senior Vice President Commercial and Enrico Dolfini as Vice President Legal Counsel Full leadership team now in place ahead…

Press Release October 31, 2019

Newly-Formed Arvelle Therapeutics Acquires Exclusive Rights from SK Biopharmaceuticals to Develop and Commercialize Cenobamate in Europe

Arvelle Therapeutics GmbH to provide SK Biopharmaceuticals an upfront payment of $100 million with future milestone potential of up to $430 million A…

Press Release February 14, 2019
Previous

Related Articles


  • The Lancet Neurology

    November 13, 2019
    Results of Randomized Study Evaluating the Safety and Efficacy of Cenobamate in Patients with Uncontrolled Focal-Onset Epilepsy Published
  • Bioworld

    November 4, 2019
    Arvelle’s CEO Mark Altmeyer Interview
Angelini Pharma Company
+41 (0) 417115882 info.ch@angelinipharma.com
LinkedIn LinkedIn Twitter Twitter
  • Home
  • Privacy Policy
Manage Cookie Consent
We use cookies to optimise your experience and our service.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}